These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29706503)

  • 1. Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy.
    Sonpavde G; Pond GR; Rosenberg JE; Choueiri TK; Bellmunt J; Regazzi AM; Mullane SA; Necchi A; Raggi D; Lee JL; Lee S; Simpson J; Derleth CL; Lin SW; Bajorin DF
    Clin Genitourin Cancer; 2018 Aug; 16(4):e961-e967. PubMed ID: 29706503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
    Necchi A; Sonpavde G; Lo Vullo S; Giardiello D; Bamias A; Crabb SJ; Harshman LC; Bellmunt J; De Giorgi U; Sternberg CN; Cerbone L; Ladoire S; Wong YN; Yu EY; Chowdhury S; Niegisch G; Srinivas S; Vaishampayan UN; Pal SK; Agarwal N; Alva A; Baniel J; Golshayan AR; Morales-Barrera R; Bowles DW; Milowsky MI; Theodore C; Berthold DR; Daugaard G; Sridhar SS; Powles T; Rosenberg JE; Galsky MD; Mariani L;
    Eur Urol; 2017 Feb; 71(2):281-289. PubMed ID: 27726966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
    Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Godbold J; Oh WK; Bamias A
    Cancer; 2013 Aug; 119(16):3012-9. PubMed ID: 23720216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
    Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
    Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
    Pond GR; Agarwal N; Bellmunt J; Choueiri TK; Qu A; Fougeray R; Vaughn D; James ND; Salhi Y; Albers P; Niegisch G; Galsky MD; Wong YN; Ko YJ; Stadler WM; O'Donnell PH; Sridhar SS; Vogelzang NJ; Necchi A; Di Lorenzo G; Sternberg CN; Mehta A; Sonpavde G
    BJU Int; 2014 May; 113(5b):E137-43. PubMed ID: 24219029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma.
    Sonpavde G; Pond GR; Rosenberg JE; Bajorin DF; Choueiri TK; Necchi A; Di Lorenzo G; Bellmunt J
    J Urol; 2016 Feb; 195(2):277-82. PubMed ID: 26292040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.
    Bambury RM; Benjamin DJ; Chaim JL; Zabor EC; Sullivan J; Garcia-Grossman IR; Regazzi AM; Ostrovnaya I; Apollo A; Xiao H; Voss MH; Iyer G; Bajorin DF; Rosenberg JE
    Oncologist; 2015 May; 20(5):508-15. PubMed ID: 25845990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nomogram for predicting survival of postcystectomy recurrent urothelial carcinoma of the bladder.
    Nakagawa T; Taguchi S; Uemura Y; Kanatani A; Ikeda M; Matsumoto A; Yoshida K; Kawai T; Nagata M; Yamada D; Komemushi Y; Suzuki M; Enomoto Y; Nishimatsu H; Ishikawa A; Nagase Y; Kondo Y; Tanaka Y; Okaneya T; Hirano Y; Shinohara M; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Igawa Y; Homma Y
    Urol Oncol; 2017 Jul; 35(7):457.e15-457.e21. PubMed ID: 28110856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
    Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain S; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Hegemann M; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Del Muro XG; Rodriguez-Vida A; Cicin I; Harputluoglu H; Widau RC; Liepa AM; Walgren RA; Hamid O; Zimmermann AH; Bell-McGuinn KM; Powles T;
    Lancet; 2017 Nov; 390(10109):2266-2277. PubMed ID: 28916371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.
    Sonpavde G; Pond GR; Di Lorenzo G; Buonerba C; Rozzi A; Lanzetta G; Necchi A; Giannatempo P; Raggi D; Matsumoto K; Choueiri TK; Mullane S; Niegisch G; Albers P; Lee JL; Kitamura H; Kume H; Bellmunt J
    Clin Genitourin Cancer; 2016 Dec; 14(6):494-498. PubMed ID: 27262369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Bukowski RM; Figlin RA; Hutson TE; Michaelson MD; Kim ST; Baum CM; Kattan MW
    Cancer; 2008 Oct; 113(7):1552-8. PubMed ID: 18720362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
    Sonpavde G; Pond GR; Choueiri TK; Mullane S; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Buonerba C; Rozzi A; Matsumoto K; Lee JL; Kitamura H; Kume H; Bellmunt J
    Eur Urol; 2016 Apr; 69(4):634-641. PubMed ID: 26264159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.
    Pal SK; Hoffman-Censits J; Zheng H; Kaiser C; Tayama D; Bellmunt J
    Eur Urol; 2018 May; 73(5):800-806. PubMed ID: 29478735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. External validation of preoperative and postoperative nomograms for prediction of cancer-specific survival, overall survival and recurrence after robot-assisted radical cystectomy for urothelial carcinoma of the bladder.
    Al-Daghmin A; English S; Kauffman EC; Din R; Khan A; Syed JR; Sztorc J; Mehedint D; Sharif M; Shi Y; Wilding G; Guru KA
    BJU Int; 2014 Aug; 114(2):253-60. PubMed ID: 24119175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
    Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M
    Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel for the treatment of bladder cancer.
    Albany C; Sonpavde G
    Expert Opin Investig Drugs; 2015; 24(12):1657-64. PubMed ID: 26535615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for metastatic urothelial carcinoma undergoing cisplatin-based salvage chemotherapy.
    Taguchi S; Nakagawa T; Hattori M; Niimi A; Nagata M; Kawai T; Fukuhara H; Nishimatsu H; Ishikawa A; Kume H; Homma Y
    Jpn J Clin Oncol; 2013 Sep; 43(9):923-8. PubMed ID: 23888082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External validation of nomograms for prediction of progression-free survival and liver toxicity in patients with advanced renal cell carcinoma treated with pazopanib.
    Okamura Y; Hinata N; Terakawa T; Furukawa J; Harada K; Nakano Y; Nakamura I; Inoue T; Ogawa T; Fujisawa M
    Int J Clin Oncol; 2019 Jun; 24(6):698-705. PubMed ID: 30798395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
    Powles T; Durán I; van der Heijden MS; Loriot Y; Vogelzang NJ; De Giorgi U; Oudard S; Retz MM; Castellano D; Bamias A; Fléchon A; Gravis G; Hussain S; Takano T; Leng N; Kadel EE; Banchereau R; Hegde PS; Mariathasan S; Cui N; Shen X; Derleth CL; Green MC; Ravaud A
    Lancet; 2018 Feb; 391(10122):748-757. PubMed ID: 29268948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Atezolizumab (Tecentriq
    Bernard-Tessier A; Bonnet C; Lavaud P; Gizzi M; Loriot Y; Massard C
    Bull Cancer; 2018 Feb; 105(2):140-145. PubMed ID: 29290331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.